Your browser is no longer supported. Please, upgrade your browser.
ACIU AC Immune SA daily Stock Chart
ACIU [NASD]
AC Immune SA
Index- P/E- EPS (ttm)-0.38 Insider Own47.90% Shs Outstand71.88M Perf Week-6.81%
Market Cap329.50M Forward P/E- EPS next Y-0.80 Insider Trans0.00% Shs Float38.03M Perf Month-47.69%
Income-27.00M PEG- EPS next Q-0.28 Inst Own28.90% Short Float5.23% Perf Quarter-32.71%
Sales52.60M P/S6.26 EPS this Y177.60% Inst Trans0.16% Short Ratio4.34 Perf Half Y-38.25%
Book/sh3.81 P/B1.22 EPS next Y15.80% ROA-8.40% Target Price- Perf Year-10.58%
Cash/sh4.05 P/C1.15 EPS next 5Y- ROE-9.10% 52W Range4.07 - 13.00 Perf YTD-45.42%
Dividend- P/FCF- EPS past 5Y26.30% ROI16.20% 52W High-64.23% Beta0.76
Dividend %- Quick Ratio20.60 Sales past 5Y29.70% Gross Margin- 52W Low14.25% ATR0.37
Employees115 Current Ratio20.60 Sales Q/Q-13.30% Oper. Margin-49.40% RSI (14)27.33 Volatility4.88% 5.61%
OptionableYes Debt/Eq0.01 EPS Q/Q8.30% Profit Margin-51.20% Rel Volume0.61 Prev Close4.77
ShortableYes LT Debt/Eq0.01 EarningsAug 05 BMO Payout- Avg Volume458.39K Price4.65
Recom1.70 SMA20-8.70% SMA50-29.96% SMA200-35.80% Volume278,554 Change-2.52%
Feb-01-19Downgrade UBS Buy → Neutral
Jan-04-19Initiated UBS Buy
Apr-05-18Initiated H.C. Wainwright Buy $18
Mar-23-18Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Outperform
Oct-18-16Initiated Jefferies Buy $25
Oct-18-16Initiated Credit Suisse Outperform $18
Oct-09-20 08:25AM  
Oct-05-20 06:39AM  
Sep-24-20 10:35AM  
Sep-23-20 10:19AM  
07:00AM  
Sep-11-20 07:00AM  
Sep-01-20 08:54AM  
Aug-21-20 08:05AM  
Aug-07-20 10:53AM  
Aug-06-20 12:00PM  
Aug-05-20 11:25AM  
07:00AM  
Aug-03-20 07:00AM  
Jul-30-20 07:55AM  
Jul-28-20 07:00AM  
Jul-23-20 07:00AM  
Jul-17-20 10:04AM  
07:41AM  
Jul-16-20 04:25PM  
03:01PM  
08:29AM  
07:00AM  
Jul-07-20 09:00AM  
06:51AM  
Jul-04-20 02:59PM  
Jun-26-20 07:21AM  
May-15-20 07:00AM  
May-06-20 10:12AM  
May-04-20 08:35AM  
07:00AM  
Apr-28-20 11:16AM  
Apr-04-20 08:04AM  
Apr-02-20 07:00AM  
Mar-30-20 07:00AM  
Mar-24-20 10:31AM  
Mar-23-20 07:00AM  
Mar-20-20 07:19AM  
Mar-18-20 09:43AM  
Mar-13-20 09:22AM  
Mar-05-20 07:00AM  
Feb-24-20 07:23AM  
Jan-30-20 10:37AM  
Dec-24-19 04:57AM  
Dec-16-19 01:46PM  
Nov-14-19 07:00AM  
Nov-13-19 07:00AM  
Nov-11-19 07:50AM  
Nov-08-19 10:25AM  
Nov-06-19 04:05PM  
02:31PM  
Nov-05-19 10:33AM  
Oct-24-19 07:00AM  
Sep-25-19 08:52AM  
Sep-23-19 01:22PM  
Sep-20-19 10:02AM  
07:00AM  
Sep-17-19 02:00AM  
Sep-04-19 07:00AM  
Aug-19-19 12:31PM  
Aug-14-19 07:00AM  
Aug-12-19 07:00AM  
Aug-07-19 10:30AM  
Jul-18-19 10:26AM  
Jul-17-19 07:00AM  
Jul-11-19 08:00AM  
Jul-10-19 10:52AM  
Jun-29-19 06:07PM  
Jun-28-19 08:36AM  
Jun-27-19 07:00AM  
Jun-20-19 07:00AM  
May-15-19 08:35AM  
07:36AM  
07:00AM  
May-08-19 01:27PM  
Apr-24-19 10:33AM  
Apr-09-19 07:02AM  
Apr-03-19 09:58AM  
Apr-01-19 07:00AM  
Mar-29-19 02:00AM  
Mar-27-19 10:48AM  
07:00AM  
Mar-26-19 09:00AM  
Mar-21-19 07:00AM  
Mar-04-19 09:59AM  
Feb-21-19 08:55AM  
Feb-20-19 08:54AM  
07:35AM  
07:00AM  
Feb-07-19 07:00AM  
Feb-06-19 09:10AM  
Feb-01-19 08:37AM  
Jan-30-19 04:47PM  
04:42PM  
11:41AM  
10:16AM  
09:49AM  
01:36AM  
01:00AM  
Jan-25-19 10:30AM  
Jan-23-19 10:01AM  
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.